文献速递头痛与眩晕神经重症与神经感染

美国曲普坦与麦角胺过量分析:国家毒物数据系统回顾

Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System.
PubMed 文献 · Neurology · 2019-12-02

该研究回顾美国国家毒物数据系统2014-2018年数据,分析曲普坦和麦角胺故意过量的临床结局。共纳入1489例,单一暴露严重效应<1%且无死亡;曲普坦中毒表现为高血压、心动过速和嗜睡,麦角胺为急性胃肠综合征伴眩晕和麻木;无血清素综合征病例。年龄、多药暴露及合用苯二氮䓬或三环类抗抑郁药增加严重事件或死亡风险。

要点

  • 曲普坦过量严重效应或死亡风险低,单药暴露无死亡记录。
  • 曲普坦中毒综合征:高血压、心动过速、嗜睡;麦角胺:胃肠症状伴眩晕麻木。
  • 合用苯二氮䓬或三环类抗抑郁药显著增加严重结局风险。

核心结论

  • 曲普坦和麦角胺过量导致严重效应或死亡的风险低,风险因素包括年龄、多药暴露及合用苯二氮䓬或三环类抗抑郁药。

研究设计与样本

  • 5年回顾性横断面研究,基于美国国家毒物数据系统(NPDS)2014-2018年数据,共纳入1489例故意过量暴露病例。

主要发现

  • 多药暴露最常见(n=1145),平均年龄31.2岁,女性1197例(80.4%)。
  • 单一暴露严重效应<1%,无死亡记录;90例(26.2%)无临床效应。
  • 曲普坦暴露(n=328)常见高血压(14%)、心动过速(10.7%)、嗜睡(11%)。
  • 麦角胺暴露(n=16)常见腹痛(16%)、呕吐(12.5%)、麻木(12.5%)。
  • 无病例符合Hunter标准诊断血清素综合征。

关键数值与推荐

  • 年龄每增加1岁,严重事件或死亡风险OR 1.02(95%CI 1.01-1.04;p=0.004)。
  • 多药暴露OR 9.50(95%CI 2.29-39.48;p=0.002)。
  • 合用苯二氮䓬OR 1.71(95%CI 1.05-2.78;p=0.032)。
  • 合用三环类抗抑郁药OR 3.16(95%CI 1.88-5.31;p<0.001)。

临床怎么用

  • 对曲普坦或麦角胺过量患者,应评估年龄、多药暴露及合用苯二氮䓬或三环类抗抑郁药等风险因素。
  • 识别曲普坦中毒综合征(高血压、心动过速、嗜睡)和麦角胺中毒(胃肠症状、眩晕、麻木)有助于临床判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the clinical outcomes of intentional overdoses involving triptans and ergotamines with a retrospective review of the National Poison Data System (NPDS). METHODS: This was a 5-year retrospective cross-sectional study (2014-2018) using the NPDS. Demographics, exposure characteristics, and outcomes were described. Univariate logistic regression was used to estimate the odds ratio (OR) for major effect or death. A multivariable logistic regression model with inclusion criteria of p < 0.1 in univariate analysis was implemented with backwards selection. RESULTS: In this population (n = 1,489), multiple exposure was most common (n = 1,145). The mean age was 31.2 years and 1,197 (80.4%) participants were female. Major effects from a single exposure were seen in <1% with no recorded deaths. Triptan ingestion (n = 328) resulted in hypertension (14%), tachycardia (10.7%), drowsiness (11%), nausea (6.4%), vomiting (4.6%), vertigo (4%), chest pain (3.7%), and diaphoresis (2.4%). Ergotamine ingestion (n = 16) resulted in abdominal pain (16%), vomiting (12.5%), numbness (12.5%), nausea (6.3%), diarrhea (6.3%), and vertigo (6.3%). No clinical effect was seen in 90 (26.2%). No cases met Hunter criteria for serotonin syndrome. There is risk of major event or death due to age (OR 1.02; 95% confidence interval [CI] 1.01-1.04; p = 0.004), multiple product exposure (OR 9.50; 95% CI 2.29-39.48; p = 0.002), and concomitant overdose with benzodiazepines (OR 1.71; 95% CI 1.05-2.78; p = 0.032) or tricyclic antidepressants (OR 3.16; 95% CI 1.88-5.31; p < 0.001). CONCLUSION: The risk of major effect or death was low and predicted by age, multiple product exposure, and concomitant benzodiazepine or tricyclic antidepressant. The triptan toxidrome consists of hypertension, tachycardia, and drowsiness. The toxic effects of ergotamine are acute gastrointestinal syndrome with vertigo and numbness. No cases of serotonin syndrome were seen.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Robblee JV, Butterfield RJ, Kang AM, et al. Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System. Neurology. 2019. PMID: 31792093. doi:10.1212/WNL.0000000000008685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。